Yahoo
NasdaqCM - Delayed Quote USD

XTL Biopharmaceuticals Ltd. (XTLB)

3.5600 +1.2500 (+54.11%)
At close: 4:00:00 PM EDT
3.3401 -0.2199 (-6.18%)
After hours: 5:37:19 PM EDT
Chart Range Bar
Loading chart for XTLB
  • Previous Close 2.3100
  • Open 3.8000
  • Bid 2.6300 x 200
  • Ask 4.3600 x 200
  • Day's Range 3.2200 - 4.8700
  • 52 Week Range 2.1200 - 10.2800
  • Volume 113,444,310
  • Avg. Volume 11,228
  • Market Cap (intraday) 8.422M
  • Beta (5Y Monthly) 0.68
  • PE Ratio (TTM) --
  • EPS (TTM) -3.6000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

www.xtlbio.com

10

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: XTLB

Trailing total returns as of 4/29/2026, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .

YTD Return

XTLB
27.14%
TA-125 (^TA125.TA)
17.99%

1-Year Return

XTLB
34.07%
TA-125 (^TA125.TA)
68.64%

3-Year Return

XTLB
20.54%
TA-125 (^TA125.TA)
0.00%

5-Year Return

XTLB
76.08%
TA-125 (^TA125.TA)
151.50%

Earnings Trends: XTLB

View More

Earnings Per Share (Normalized)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY16
Revenue --
Earnings --

Q2

FY15

Q3

FY15

Q4

FY15

Q1

FY16

-500K
-400K
-300K
-200K
-100K
0

Statistics: XTLB

View More

Valuation Measures

Annual
As of 4/28/2026
  • Market Cap

    5.72M

  • Enterprise Value

    5.55M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.18

  • Price/Book (mrq)

    0.97

  • Enterprise Value/Revenue

    5.73

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -240.56%

  • Return on Equity (ttm)

    -577.13%

  • Revenue (ttm)

    968k

  • Net Income Avi to Common (ttm)

    -6.31M

  • Diluted EPS (ttm)

    -3.6000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    259k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Compare To: XTLB

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: XTLB

Fair Value

3.5600 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: